格林生物
(301688)
| 流通市值：8.69亿 | | | 总市值：44.61亿 |
| 流通股本：2598.50万 | | | 总股本：1.33亿 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 878,834,434.37 | 98,491,509.12 | - | 71,837,759.59 |
| 应收票据及应收账款 | 239,278,729.62 | 243,294,333.08 | - | 192,243,110.3 |
| 其中：应收票据 | 20,113.92 | 130,264 | - | 104,538.74 |
| 应收账款 | 239,258,615.7 | 243,164,069.08 | - | 192,138,571.56 |
| 应收款项融资 | 18,763,107.31 | 26,979,604.24 | - | 19,250,059.26 |
| 预付款项 | 3,997,346.98 | 2,837,742.55 | - | 4,244,449.18 |
| 其他应收款合计 | 1,274,958.56 | 546,036.22 | - | 1,024,103.74 |
| 存货 | 480,773,029.03 | 411,375,332.59 | - | 358,236,109.32 |
| 其他流动资产 | 12,768,443.97 | 12,120,205.34 | - | 58,682,161.28 |
| 流动资产平衡项目 | 0 | 0 | - | 0 |
| 流动资产合计 | 1,635,690,049.84 | 795,644,763.14 | - | 705,517,752.67 |
| 非流动资产: | | | | |
| 固定资产 | 922,269,917.16 | 935,719,501.13 | - | 935,130,621.11 |
| 在建工程 | 39,649,003.03 | 33,150,010.2 | - | 31,294,906.09 |
| 使用权资产 | 879,773.54 | 1,268,580.06 | - | 2,145,408.03 |
| 无形资产 | 83,032,583.33 | 83,833,129.61 | - | 85,104,323.43 |
| 长期待摊费用 | 9,931,572.52 | 8,252,673.62 | - | 8,892,775.04 |
| 递延所得税资产 | 4,181,162.36 | 4,239,671.12 | - | 4,024,419.84 |
| 其他非流动资产 | 5,148,821.45 | 5,780,286.24 | - | 5,593,720.21 |
| 非流动资产平衡项目 | 0 | 0 | - | 0 |
| 非流动资产合计 | 1,065,092,833.39 | 1,072,243,851.98 | - | 1,072,186,173.75 |
| 资产平衡项目 | 0 | 0 | - | 0 |
| 资产总计 | 2,700,782,883.23 | 1,867,888,615.12 | 1,850,300,000 | 1,777,703,926.42 |
| 流动负债: | | | | |
| 短期借款 | 420,580,513.8 | 345,233,436.08 | - | 227,568,150.27 |
| 应付票据及应付账款 | 136,884,736.07 | 136,964,994.79 | - | 156,044,371.24 |
| 应付账款 | 136,884,736.07 | 136,964,994.79 | - | 156,044,371.24 |
| 合同负债 | 3,535,393.36 | 3,126,612.3 | - | 6,160,369.58 |
| 应付职工薪酬 | 23,346,248.39 | 17,505,690.29 | - | 16,952,254.74 |
| 应交税费 | 12,025,305.01 | 11,179,457.09 | - | 13,526,337.49 |
| 其他应付款合计 | 4,618,183.58 | 752,937.98 | - | 803,126.6 |
| 一年内到期的非流动负债 | 73,294,839.7 | 111,249,448.79 | - | 118,132,431.04 |
| 其他流动负债 | 79,042.35 | 195,370.33 | - | 185,513.1 |
| 流动负债平衡项目 | 0 | 0 | - | 0 |
| 流动负债合计 | 674,364,262.26 | 626,207,947.65 | - | 539,372,554.06 |
| 非流动负债: | | | | |
| 长期借款 | 355,961,596.38 | 382,742,395.73 | - | 481,275,960.2 |
| 递延收益 | 6,699,181.46 | 6,869,114.36 | - | 7,208,980.16 |
| 递延所得税负债 | 657,813.17 | 983,495.09 | - | 1,163,151.24 |
| 非流动负债平衡项目 | 0 | 0 | - | 0 |
| 非流动负债合计 | 363,318,591.01 | 390,595,005.18 | - | 489,648,091.6 |
| 负债平衡项目 | 0 | 0 | - | 0 |
| 负债合计 | 1,037,682,853.27 | 1,016,802,952.83 | 1,049,576,900 | 1,029,020,645.66 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 133,333,334 | 100,000,000 | - | 100,000,000 |
| 资本公积 | 808,861,531.86 | 71,751,030.76 | - | 71,751,030.76 |
| 其他综合收益 | 778,317.22 | 1,141,819.34 | - | 816,061.17 |
| 专项储备 | 25,962,344.22 | 24,320,816.3 | - | 20,765,418.72 |
| 盈余公积 | 57,626,112.02 | 44,903,094.6 | - | 44,903,094.6 |
| 未分配利润 | 636,538,390.64 | 608,968,901.29 | - | 510,447,675.51 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | - | 0 |
| 归属于母公司股东权益合计 | 1,663,100,029.96 | 851,085,662.29 | 800,723,100 | 748,683,280.76 |
| 股东权益平衡项目 | 0 | 0 | - | 0 |
| 股东权益合计 | 1,663,100,029.96 | 851,085,662.29 | - | 748,683,280.76 |
| 负债和股东权益合计 | 2,700,782,883.23 | 1,867,888,615.12 | - | 1,777,703,926.42 |
| 公告日期 | 2026-10-22 | 2026-08-06 | 2026-04-22 | 2026-04-22 |
| 审计意见(境内) | | | | 标准无保留意见 |